Chao Gao

Dr. Chao Gao


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2025 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
ZDZening Dong
Zening Dong
ZYZhangchen Yuan
Zhangchen Yuan
TJTianqiang Jin
Tianqiang Jin
CGChao Gao
Chao Gao
XWXiaoyu Wang
Xiaoyu Wang
FXFeng Xu
Feng Xu
Lactate, initially considered a mere metabolic byproduct, has emerged as a pivotal metabolite in the tumor microenvironment (TME), playing critical roles across a range of pathological conditions. In tumors in particular, lactate contributes to disease progression through its multifaceted biological functions. Recent studies have further identified lactate as a central mediator in the regulation of tumor immune evasion. Tumor cells, via aerobic glycolysis, secrete large amounts of lactate, leading to acidification of the TME and suppression of antitumor immunity through various mechanisms, including immune cell inhibition, epigenetic reprogramming, and metabolic competition. These findings have fueled growing interest in targeting lactate as a therapeutic strategy against cancer, encompassing approaches such as LDHA inhibitors, MCT inhibitors, and novel nanomedicine-based therapies. In this review, we summarize lactate metabolism in the body, explore its impact on various immune cell populations, elucidate its functional roles in tumor biology, and highlight recent advances in antitumor strategies that target lactate.

26 January 2024 in Pharmacological Research
Verified
Journal Article
Open access
YHYilan Huang
Yilan Huang
SWSiwei Wang
Siwei Wang
XZXiaojun Zhang
Xiaojun Zhang
CYChen Yang
Chen Yang
SWSikai Wang
Sikai Wang
KGKun Guo
Kun Guo
Lenvatinib is a frontline tyrosine kinase inhibitor for patients with advanced hepatocellular carcinoma (HCC). However, just 25% of patients benefit from the treatment, and acquired resistance always develops. To date, there are neither effective medications to combat lenvatinib resistance nor accurate markers that might predict how well a patient would respond to the lenvatinib treatment. Thus, novel strategies to recognize and deal with lenvatinib resistance are desperately needed. In the current study, a robust Lenvatinib Resistance index (LRi) model to predict lenvatinib response status in HCC was first established. Subsequently, five candidate drugs (Mercaptopurine, AACOCF3, NU1025, Fasudil, and Exisulind) that were capable of reversing lenvatinib resistance signature were initially selected by performing the connectivity map (CMap) analysis, and fasudil finally stood out by conducting a series of cellular functional assays in vitro and xenograft mouse model. Transcriptomics revealed that the co-administration of lenvatinib and fasudil overcame lenvatinib resistance by remodeling the hedgehog signaling pathway. Mechanistically, the feedback activation of EGFR by lenvatinib led to the activation of the GLI2-ABCC1 pathway, which supported the HCC cell's survival and proliferation. Notably, co-administration of lenvatinib and fasudil significantly inhibited IHH, the upstream switch of the hedgehog pathway, to counteract GLI2 activation and finally enhance the effectiveness of lenvatinib. These findings elucidated a novel EGFR-mediated mechanism of lenvatinib resistance and provided a practical approach to overcoming drug resistance in HCC through meaningful drug repurposing strategies.

10 July 2024 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
SWSi-Wei Wang
Si-Wei Wang
QZQiu-Yi Zheng
Qiu-Yi Zheng
WHWei-Feng Hong
Wei-Feng Hong
BTBu-Fu Tang
Bu-Fu Tang
SHShu-Jung Hsu
Shu-Jung Hsu
SDShisuo Du
Shisuo Du

23 April 2025 in Cancer Biology & Medicine
Verified
Journal Article
Open access
PDF file
LYLi Yuan
Li Yuan
YWYue Wang
Yue Wang
JCJunjie Cheng
Junjie Cheng
SLShilin Lin
Shilin Lin
AMAying Ma
Aying Ma
SDShisuo Du
Shisuo Du
Objective: Although the role of circular RNAs (circRNAs) in tumor progression and immune regulation is well-known, the specific circRNA molecules that mediate immune responses after radiotherapy (RT) and the underlying mechanisms have not been identified. Methods: Cytometry with time-of-flight (CyTOF) was used to analyze blood samples from patients with liver cancer exhibiting abscopal effects (AEs) after stereotactic body radiotherapy (SBRT) to quantify the number of dendritic cells (DCs) and CD8+ T cells and interferon-beta (IFN-β) level. circTMEM56 and IFN-β levels were measured in 76 patients with liver cancer using qPCR and ELISA. Immunohistochemistry validated circTMEM56 and CD141 staining in tissues. The interaction between circTMEM56, miR-136-5p, and STING, as well as the impact on anti-tumor immunity, was verified using circTMEM56-specific probes, dual-luciferase activity assays, proteomics analysis, and western blot analysis. Results: The role of circTMEM56 in enhancing anti-tumor immunity and response to RT in hepatocellular carcinoma (HCC) was determined. Higher circTMEM56 levels were linked to an improved RT response and better clinical outcomes in patients with HCC. circTMEM56 enhanced cGAS-STING signaling, increased the number of tumor-infiltrating CD8+ T cells, and elevated the serum IFN-β levels. Moreover, circTMEM56 administration significantly boosted the response to RT in tumors with low circTMEM56 expression. Conclusions: High circTMEM56 expression in HCC modulates the distant effects of HCC RT by activating the cGAS-STING pathway to reshape the tumor microenvironment. This study provides a new approach to improve RT efficacy for HCC.

17 December 2024 in Inflammopharmacology
Verified
Journal Article
Open access
PDF file
AMAying Ma
Aying Ma
JZJieyun Zhou
Jieyun Zhou
HZHui Zou
Hui Zou
LYLi Yuan
Li Yuan
RZRuihua Zhong
Ruihua Zhong
CGChao Gao
Chao Gao
Progesterone plays a crucial and indispensable role in regulating immunity and attenuating inflammation. Nestorone® (NES, segesterone acetate) is a steroidal progestin and a 19-norprogesterone derivative with no -CH3 group radical at the 6-position. Here, we showed that NES enhanced the viability of lipopolysaccharide (LPS)-stimulated THP-1 cell-derived macrophages, potently inhibiting both arms of the Toll-like receptor 4 (TLR-4) signaling cascade triggered by LPS, especially the TLR-4/MyD88/NF-κB pathway. In addition, NES exerted an anti-inflammatory effect by significantly decreasing the secretion of inflammatory cytokines and chemokines in type II alveolar epithelial A549 cells and THP-1 cell-derived macrophages stimulated by LPS. Furthermore, we evaluated the potential of NES pre-treatment, administered 2 h prior to LPS exposure, to mitigate acute lung injury induced by LPS, using an LPS-induced acute lung injury (ALI) mouse model. In this study, NES alleviated lung inflammation and damage by reducing leukocyte infiltration and inflammatory cytokines in the bronchoalveolar lavage fluid (BALF) and lung tissues of mice. Interestingly, our findings indicate that NES at a dosage of 1 mg/kg (91.67%) was more effective than at dosages of 0.1 mg/kg (70.83%) or 10 mg/kg (87.50%), as well as more effective than dexamethasone (DEX, 5 mg/kg, 83.34%), in extending survival in mice subjected to lethal LPS-induced injury. Additionally, this dosage was more successful in reducing acute lung inflammation and alleviating diffuse alveolar damage in the lungs of C57 mice. Our study indicates that concentration is a critical determinant of the anti-inflammatory efficacy of NES. Consequently, NES emerges as a potentially promising therapeutic agent for the treatment of pulmonary inflammatory conditions through the modulation of TLR-4 signaling pathways.

16 August 2025 in International Journal of Cancer
Verified
Journal Article
Open access
LZLongtao Zhao
Longtao Zhao
JCJunjie Cheng
Junjie Cheng
YZYiming Zheng
Yiming Zheng
JWJing Wu
Jing Wu
JFJia Fan
Jia Fan
CGChao Gao
Chao Gao
Hepatocellular carcinoma (HCC) represents the predominant form of primary liver cancer and is frequently identified at a late stage, necessitating systemic therapy. However, resistance to first‐line tyrosine kinase inhibitor therapies, such as sorafenib and lenvatinib, remains a significant clinical challenge. Recent research has revealed a strong link between aerobic glycolysis and drug resistance in HCC. Key enzymes in the glycolytic pathway, such as hexokinase, phosphofructokinase, and pyruvate kinase M, play central roles in the metabolic reprogramming of HCC cells. Aberrant activation of these enzymes not only promotes swift proliferation of tumor cells but also boosts adaptability. Lactate, the final product of glycolysis, is also pivotal in contributing to drug resistance in HCC. Moreover, signaling pathways, such as AMPK, HIF‐1, and c‐Myc, play key roles in tumor metabolic regulation, influencing energy balance, gene expression under hypoxia, and metabolic pathway control. These mechanisms interact synergistically, allowing HCC cells to endure and proliferate despite targeted therapies, ultimately resulting in drug resistance. Therefore, a deeper understanding of these metabolic and signaling regulatory mechanisms will help reveal the fundamental causes of drug resistance in HCC and provide new targets and directions for future therapeutic strategies.